TELA Bio, Inc. (NASDAQ:TELA) Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC reduced its position in TELA Bio, Inc. (NASDAQ:TELA) by 44.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,970 shares of the company’s stock after selling 28,615 shares during the quarter. Calamos Advisors LLC’s holdings in TELA Bio were worth $238,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Pentwater Capital Management LP boosted its holdings in shares of TELA Bio by 5.3% in the third quarter. Pentwater Capital Management LP now owns 925,000 shares of the company’s stock valued at $7,400,000 after acquiring an additional 46,201 shares during the period. Sectoral Asset Management Inc. lifted its holdings in shares of TELA Bio by 194.3% during the third quarter. Sectoral Asset Management Inc. now owns 525,000 shares of the company’s stock worth $4,200,000 after purchasing an additional 346,628 shares during the period. Stonepine Capital Management LLC lifted its holdings in shares of TELA Bio by 1.9% during the third quarter. Stonepine Capital Management LLC now owns 491,919 shares of the company’s stock worth $3,935,000 after purchasing an additional 9,300 shares during the period. Silverarc Capital Management LLC lifted its holdings in shares of TELA Bio by 17.8% during the third quarter. Silverarc Capital Management LLC now owns 490,471 shares of the company’s stock worth $3,924,000 after purchasing an additional 74,031 shares during the period. Finally, Paradigm Capital Management Inc. NY acquired a new stake in shares of TELA Bio during the third quarter worth $1,756,000. 94.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. JMP Securities reaffirmed a “market outperform” rating and set a $15.00 price target on shares of TELA Bio in a report on Friday, March 22nd. Piper Sandler decreased their price target on TELA Bio from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, March 22nd. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of TELA Bio in a report on Wednesday, December 27th.

TELA Bio Trading Down 3.8 %

NASDAQ:TELA opened at $4.57 on Tuesday. The stock has a fifty day moving average price of $5.87 and a two-hundred day moving average price of $6.02. The company has a current ratio of 4.23, a quick ratio of 3.45 and a debt-to-equity ratio of 2.15. TELA Bio, Inc. has a 1 year low of $4.23 and a 1 year high of $11.26.

TELA Bio (NASDAQ:TELA) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.09). The business had revenue of $17.00 million during the quarter, compared to analysts’ expectations of $16.65 million. TELA Bio had a negative return on equity of 201.62% and a negative net margin of 79.83%. As a group, equities research analysts forecast that TELA Bio, Inc. will post -1.61 earnings per share for the current fiscal year.

TELA Bio Company Profile

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.